Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 8 words
    • Site details revised
    • Study description expanded, about 2 words
  2. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2028v13
  3. Re-verified, no change to tracked fieldsv12
  4. Primary and study completion dates: Jan 30, 2026 to Dec 31, 2025v11
  5. Re-verified, no change to tracked fieldsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary and study completion dates: Jul 31, 2024 to Jan 30, 2026v9
  2. 2 versions Re-verified since Dec 7, 2023, no change to tracked fieldsv7-v8
  3. Phase: Early Phase 1 to Phase 1/2v6
  4. Re-verified, no change to tracked fieldsv5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2023 to Feb 23, 2023
    • Site details revised
    v4
  6. Start date: Nov 1, 2022 to Nov 1, 2023v3
  7. Eligibility criteria shortened, about 38 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.
Trial Details
NCT Number NCT05394337
Lead Sponsor M.D. Anderson Cancer Center
Conditions
(from sponsor)		 Metastatic Malignancy
Related terms Neoplasms
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov